港股異動丨華泰證券(6886.HK)跌4.57%創歷史新低 第三季度淨利同比降25.39%
格隆匯10月31日丨華泰證券(6886.HK)跌4.57%,報7.73港元創其上市以來新低,總市值702億港元。華泰證券發佈2022年第三季度報吿顯示,在2022年第三季度,華泰證券實現營業收入74.52億元,同比(較上年同期)減少14.09%;實現歸屬於上市公司股東的淨利潤24.46億元,同比減少25.39%。2022年前三季度,華泰證券合計實現營業收入236.18億元,同比減少12.22%;實現歸屬於上市公司股東的淨利潤78.21億元,同比減少29.21%。三季度受權益市場震盪影響,公司資金類業務承壓,自營投資表現不佳拖累公司整體業績。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.